In many malignancies, such as endometrial carcinoma [4] prostate cancer [5, 6], and glioma [7, 8], KIF4A is frequently overexpressed and contributes to tumour progression through mechanisms that enhance genomic stability, mediate therapy resistance, and modify the immune microenvironment [9–11]. Here, KIF4A is linked to prostate carcinoma.